AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 86_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 21_CD Reserves_NNS Share_NNP Capital_NNP Joint_NNP Profit_NNP premium_NN redemption_NN Merger_NNP Other_JJ ventures_NNS and_CC and_CC loss_NN account_NN reserve_NN reserve_NN reserves_NNS associates_NNS account_VBP Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD At_IN 31_CD December_NNP 2000_CD 235_CD 3_CD 433_CD 1,634_CD 183_CD 6,825_CD 8,947_CD Profit_NN retained_VBN for_IN year_NN 1,681_CD 1,681_CD Share_NN premiums_NNS 86_CD 86_CD Transfer_NN between_IN reserves_NNS 13_CD 13_CD Re-purchase_NN of_IN shares_NNS 6_CD 1,080_CD 1,074_CD Exchange_NNP adjustments_NNS :_: Goodwill_NNP 19_CD 19_CD Foreign_JJ exchange_NN adjustments_NNS on_IN consolidation_NN ,_, net_NN of_IN tax_NN 502_CD 502_CD On_IN foreign_JJ currency_NN borrowings_NNS 18_CD 18_CD Foreign_JJ currency_NN borrowings_NNS tax_NN effect_NN 6_CD 6_CD 19 509 490_CD Net_JJ movements_NNS 99_CD 6_CD 19_CD 79_CD 203_CD At_IN 31_CD December_NNP 2001_CD 334_CD 9_CD 433_CD 1,653_CD 183_CD 6,904_CD 9,150_CD Profit_NN retained_VBN for_IN year_NN 1,630_CD 1,630_CD Share_NN premiums_NNS 36_CD 36_CD Transfer_NN between_IN reserves_NNS 33_CD 33_CD Re-purchase_NN of_IN shares_NNS 7_CD 1,190_CD 1,183_CD Exchange_NNP adjustments_NNS :_: Goodwill_NNP 30_CD 30_CD Foreign_JJ exchange_NN adjustments_NNS on_IN consolidation_NN ,_, net_NN of_IN tax_NN 1,106_CD 1,106_CD On_IN foreign_JJ currency_NN borrowings_NNS 66_CD Foreign_JJ currency_NN borrowings_NNS tax_NN effect_NN 2_CD 2_CD 30_CD 1,140_CD 1,110_CD Net_JJ movements_NNS 69_CD 7_CD 30_CD 1,547_CD 1,593_CD At_IN 31_CD December_NNP 2002_CD 403_CD 16_CD 433_CD 1,623_CD 183_CD 8,451_CD 10,743_CD Profit_NN retained_VBN for_IN year_NN 1,686_CD 1,686_CD Share_NN premiums_NNS 46_CD 46_CD Re-purchase_NN of_IN shares_NNS 7_CD 1,154_CD 1,147_CD Exchange_NNP adjustments_NNS :_: Goodwill_NNP 39_CD 39_CD Foreign_JJ exchange_NN adjustments_NNS on_IN consolidation_NN ,_, net_NN of_IN tax_NN 1,427_CD 1,427_CD 39_CD 1,466_CD 1,427_CD Net_JJ movements_NNS 46_CD 7_CD 39_CD 1,998_CD 2,012_CD At_IN 31_CD December_NNP 2003_CD 449_CD 23_CD 433_CD 1,584_CD 183_CD 10,449_CD 12,755_CD The_DT cumulative_JJ amount_NN of_IN goodwill_NN resulting_VBG from_IN acquisitions_NNS ,_, net_NN of_IN disposals_NNS ,_, prior_RB to_TO the_DT adoption_NN of_IN FRS_NNP 10_CD in_IN 1998_CD ,_, amounted_VBD to_TO $_$ 656m_CD 2002_CD $_$ 617m_CD ,_, 2001_CD $_$ 587m_CD using_VBG year_NN end_NN rates_NNS of_IN exchange_NN ._.
There_EX are_VBP no_DT significant_JJ statutory_JJ or_CC contractual_JJ restrictions_NNS on_IN the_DT distribution_NN of_IN current_JJ profits_NNS of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS or_CC associates_NNS :_: undistributed_JJ profits_NNS of_IN prior_JJ years_NNS are_VBP ,_, in_IN the_DT main_JJ ,_, permanently_RB employed_VBN in_IN the_DT businesses_NNS of_IN these_DT companies_NNS ._.
The_DT undistributed_JJ income_NN of_IN AstraZeneca_NNP companies_NNS overseas_RB may_MD be_VB liable_JJ to_TO overseas_JJ taxes_NNS and_CC or_CC UK_NNP taxation_NN after_IN allowing_VBG for_IN double_JJ taxation_NN relief_NN if_IN they_PRP were_VBD to_TO be_VB distributed_VBN as_IN dividends_NNS see_VBP Note_NN 5_CD ._.
